Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE8A | O60658 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21076558 | 0.84 | TLR7 (0.57) | TLR7ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL21076817 | 0.82 | TLR7 (0.59) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23764385 | 0.79 | PDE8A (0.59) | TLR7ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL19539581 | 0.78 | TLR7 (0.59) | TLR7ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL12305263 | 0.77 | CYP3A4 (0.47) | TLR7AXLTYRO3MERTKADORA2A | |
| SCHEMBL3959301 | 0.76 | PDE4A (0.53) | TLR7AXLTYRO3MERTKADORA2A | |
| SCHEMBL3955278 | 0.76 | AXL (0.56) | TLR7AXLTYRO3MERTKADORA2A | |
| SCHEMBL21076762 | 0.74 | TLR7 (1.00) | TLR7 | |
| SCHEMBL21449005 | 0.74 | TLR7 (0.47) | TLR7ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL23421267 | 0.73 | TLR7 (0.48) | TLR7PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703755-B2 | Substituted purine derivative | TLR7, TLR9, TLR1 | TLR7 1/4885AXL 2383/4885TYRO3 640/4885 |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | TLR7, TLR9, TLR1 | TLR7 1/4885AXL 2383/4885TYRO3 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.